HOME ·

KEYMED BIO-B

KEYMED BIO-B (02162.HK): Nine-Month Product Revenue up 227%, Teen AD Indication Approved
Tags：
KEYMED BIO-B02162.HKBusiness Updates
2026-10-16
KEYMED BIO-B (02162.HK): Non-Executive Director Dr. Wang Minchuan Resigns, Effective 4 September 2026
Tags：
KEYMED BIO-B02162.HK
2026-09-07
KEYMED BIO-B (02162.HK): Exclusive License Agreement for Stapokibart Covering 18 Countries and Regions Including Southeast Asia and Central Asia
Tags：
KEYMED BIO-B02162.HKLicensing
2026-09-02
KEYMED BIO-B(02162.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 1.22 billion, turned profitable from a loss YoY
Tags：
KEYMED BIO-B02162.HKturned profitable from loss
2026-08-20
KEYMED BIO-B (02162.HK): Proposes RMB Share Issuance and STAR Market Listing on Shanghai Stock Exchange, Subject to Shareholder and Regulatory Approvals
Tags：
KEYMED BIO-B02162.HKA+H
2026-08-19
KEYMED BIO-B (02162.HK): Phase II trial of CM512 (TSLP x IL-13 bispecific antibody) for chronic rhinosinusitis with nasal polyps meets all study endpoints; Phase III to advance with 300mg once-half-yearly regimen
Tags：
KEYMED BIO-B02162.HKR&D Progress
2026-08-10
KEYMED BIO-B (02162.HK): Global Phase III Trial of CMG901 (AZD0901) Meets Primary Endpoint, Delivers Improved OS for 2L+ Gastric Cancer; AstraZeneca Forecasts Peak Sales of USD3-5 Billion
Tags：
KEYMED BIO-B02162.HKAstraZenecaClinical Trial
2026-07-28
KEYMED BIO-B (02162.HK): CM512 (TSLP/IL-13 Bispecific Antibody) Granted Breakthrough Therapy Designation by NMPA
Tags：
KEYMED BIO-B02162.HKCDEBreakthrough Therapy
2026-07-23